Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit

Trial Profile

Study of the Decongestant Effect of the Combination of Loratadine and Montelukast Compared With Placebo in SAR Subjects Exposed to Pollen in an Environmental Exposure Unit

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Loratadine/montelukast (Primary) ; Phenylephrine
  • Indications Seasonal allergic rhinitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 01 Apr 2009 Results reported in Annals of Allergy, Asthma and Immunology.
    • 27 Jun 2008 Schering-Plough and Merck and Co withdraw NDA for loratadine/montelukast combination tablet according to Schering-Plough media release.
    • 10 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top